Gilead Sciences' Q2 Earnings Call: Growth, Strategic Advances, and Positive Outlook

Gilead Sciences reported a 4% YoY growth in base business sales to $6.9 billion, driven by strong performance of products like Biktarvy and Descovy. The company celebrated the successful launch of Yeztugo, a twice-yearly HIV prevention injection, and increased its full-year revenue and EPS guidance. However, Veklury sales declined 44% YoY, and the cell therapy segment faced challenges with a 7% YoY sales decline.

Gilead Sciences, Inc. (Nasdaq: GILD) reported its second quarter 2025 financial results, showcasing a 4% year-over-year (YoY) growth in base business sales to $6.9 billion. The company attributed this growth to robust performance in key products such as Biktarvy and Descovy. The quarter also saw the successful launch of Yeztugo, a twice-yearly HIV prevention injection, which was approved by the U.S. Food and Drug Administration (FDA) [1].

The company's total revenue increased by 2% to $7.1 billion, driven by higher HIV, Livdelzi, and Trodelvy sales, partially offset by lower chronic hepatitis C virus (HCV) and Veklury sales. Diluted earnings per share (EPS) rose to $1.56, up from $1.29 in the same period last year. This increase was primarily due to net unrealized gains on securities and higher product sales, partially offset by a pre-tax in-process research and development (IPR&D) impairment charge of $190 million related to the MYR GmbH acquisition and higher R&D expenses [1].

Key product sales highlights include:
- Biktarvy sales increased by 9% to $3.5 billion, driven by higher demand.
- Descovy sales surged by 35% to $653 million, primarily due to higher average realized price and demand.
- HIV product sales increased by 7% to $5.1 billion.
- Veklury sales declined by 44% to $121 million, primarily due to lower rates of COVID-19-related hospitalizations.

The company also faced challenges in the cell therapy segment, with a 7% YoY sales decline to $485 million. This was partially offset by higher average realized prices for Yescarta and Tecartus, with Yescarta sales decreasing by 5% and Tecartus sales decreasing by 14% [1].

Gilead increased its full-year revenue and EPS guidance for 2025, reflecting the company's confidence in its product portfolio and pipeline. The company expects product sales to range between $28.3 billion and $28.7 billion, with non-GAAP diluted EPS expected to range between $7.95 and $8.25 [1].

The company's strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to accelerate access to twice-yearly lenacapavir for HIV prevention in low- and lower-middle-income countries was also announced [1].

References:
[1] Gilead Sciences Announces Second Quarter 2025 Financial Results. (2025). Retrieved from [https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Second-Quarter-2025-Financial-Results/default.aspx](https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Second-Quarter-2025-Financial-Results/default.aspx)